DigestRedComo funciona
Digest/ Comunicado

RECORDATI: FDA GRANTS ISTURISA® (OSILODROSTAT) EXPANDED INDICATION FOR THE TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN PATIENTS WITH CUSHING’S SYNDROME

Compatibilidad
Ahorrar(0)
Compartir
RECORDATI: FDA GRANTS ISTURISA® (OSILODROSTAT) EXPANDED INDICATION FOR THE TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN PATIENTS WITH CUSHING’S SYNDROME
Materiales adjuntos (1)

216_153452_2025_oneinfo.pdf

Descargar kit de prensa ->
Detalles de contacto

Comunicados relacionados

16/04/2025
Biotecnología
Publicidad/Marketing/Medios de comunicación/Comunicación
Anuncios breves
RECORDATI: FDA GRANTS ISTURISA® (OSILODROSTAT) EXPANDED INDICATION FOR THE TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN PATIENTS WITH CUSHING’S SYNDROME
Fuente
RECORDATI
Editor
GLOBENEWSWIRE
Descubre afinidades
0
Press Release cover image
11/11/2025
Biotecnología
Publicidad/Marketing/Medios de comunicación/Comunicación
Anuncios breves
RECORDATI FIRST NINE MONTHS 2025 RESULTS: REVENUE +12.2%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +10.7%; ISTURISA PEAK SALES ESTIMATE DOUBLED TO GREATER THAN € 1.2 BILLION
Fuente
RECORDATI
Editor
GLOBENEWSWIRE
Descubre afinidades
0
11/11/2025
Finanzas
Ahorro/Finanzas personales
Fondos de inversión
Industria
RECORDATI FIRST NINE MONTHS 2025 RESULTS: REVENUE +12.2%, EBITDA +11.8%, ADJUSTED NET INCOME +10.7%; ISTURISA PEAK SALES ESTIMATE DOUBLED TO GREATER THAN € 1.2 BILLION
Fuente
RECORDATI
Editor
1INFO
Descubre afinidades
0